Form 4: Salarius Pharmaceuticals CFO Receives Stock Grant
Insider Transaction (Form 4)
Mark J Rosenblum, Chief Financial Officer of Salarius Pharmaceuticals, Inc., received 9,682 shares of common stock on August 31, 2026.
Summary
- Grant/award: acquired 9,682 Common Stock on August 31, 2026; holds 11,363 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Mark J Rosenblum — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-31 | Grant/award | Common Stock | 9,682 | — | — | 11,363 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-31 | Grant/award (9,682 shares) |
Keywords
insider transaction, Form 4, DCOY, Decoy Therapeutics Inc., neutral, Mark J Rosenblum
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.